{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:11:25Z","timestamp":1771481485119,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T00:00:00Z","timestamp":1403222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T00:00:00Z","timestamp":1403222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/leu.2014.199","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T06:38:06Z","timestamp":1403246286000},"page":"346-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"29","author":[{"given":"R","family":"Mani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F W","family":"Frissora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-L","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Baskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-S","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Muthusamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,20]]},"reference":[{"key":"BFleu2014199_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS . Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219\u2013234.","journal-title":"Blood"},{"key":"BFleu2014199_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","volume":"40","author":"JL Binet","year":"1977","unstructured":"Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855\u2013864.","journal-title":"Cancer"},{"key":"BFleu2014199_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.clinthera.2013.08.004","volume":"35","author":"AV Danilov","year":"2013","unstructured":"Danilov AV . Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther 2013; 35: 1258\u20131270.","journal-title":"Clin Ther"},{"key":"BFleu2014199_CR4","doi-asserted-by":"crossref","unstructured":"Davids MS, Brown JR . Targeting the B Cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012.","DOI":"10.3109\/10428194.2012.695781"},{"key":"BFleu2014199_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 2005; 8: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFleu2014199_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","volume":"157","author":"Q Zhang","year":"2000","unstructured":"Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA . Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000; 157: 1137\u20131146.","journal-title":"Am J Pathol"},{"key":"BFleu2014199_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0002-9440(10)62535-7","volume":"159","author":"T Oka","year":"2001","unstructured":"Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas\/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 2001; 159: 1495\u20131505.","journal-title":"Am J Pathol"},{"key":"BFleu2014199_CR8","first-page":"6390","volume":"62","author":"T Oka","year":"2002","unstructured":"Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias\/lymphomas. Cancer Res 2002; 62: 6390\u20136394.","journal-title":"Cancer Res"},{"key":"BFleu2014199_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2141.2005.05412.x","volume":"129","author":"MF Johan","year":"2005","unstructured":"Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT . Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005; 129: 60\u201365.","journal-title":"Br J Haematol"},{"key":"BFleu2014199_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2006-10-053884","volume":"111","author":"Q Liu","year":"2008","unstructured":"Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia\/lymphoma. Blood 2008; 111: 275\u2013284.","journal-title":"Blood"},{"key":"BFleu2014199_CR11","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-09-2484","volume":"16","author":"Q Liu","year":"2010","unstructured":"Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010; 16: 3182\u20133192.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014199_CR12","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1182\/blood-2011-06-363879","volume":"118","author":"L Alinari","year":"2011","unstructured":"Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood 2011; 118: 6893\u20136903.","journal-title":"Blood"},{"key":"BFleu2014199_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ijc.21243","volume":"117","author":"CW Chua","year":"2005","unstructured":"Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 2005; 117: 1039\u20131048.","journal-title":"Int J Cancer"},{"key":"BFleu2014199_CR14","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1172\/JCI31095","volume":"117","author":"P Neviani","year":"2007","unstructured":"Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408\u20132421.","journal-title":"J Clin Invest"},{"key":"BFleu2014199_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-07-2621","volume":"68","author":"JH Hung","year":"2008","unstructured":"Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 2008; 68: 1204\u20131212.","journal-title":"Cancer Res"},{"key":"BFleu2014199_CR16","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/hep.24293","volume":"53","author":"HA Omar","year":"2011","unstructured":"Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011; 53: 1943\u20131958.","journal-title":"Hepatology"},{"key":"BFleu2014199_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","volume":"14","author":"S Baskar","year":"2008","unstructured":"Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 396\u2013404.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014199_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ijc.23587","volume":"123","author":"AH Daneshmanesh","year":"2008","unstructured":"Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123: 1190\u20131195.","journal-title":"Int J Cancer"},{"key":"BFleu2014199_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen ZG, Shin DM . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771\u2013782.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2014199_CR20","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990\u20134997.","journal-title":"Blood"},{"key":"BFleu2014199_CR21","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.4049\/jimmunol.176.4.2208","volume":"176","author":"HC Chen","year":"2006","unstructured":"Chen HC, Byrd JC, Muthusamy N . Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival. J Immunol 2006; 176: 2208\u20132218.","journal-title":"J Immunol"},{"key":"BFleu2014199_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskjot","year":"2003","unstructured":"Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33: 90\u201396.","journal-title":"Nat Genet"},{"key":"BFleu2014199_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2010.09.019","volume":"402","author":"H Li","year":"2010","unstructured":"Li H, Lu Y, Piao L, Wu J, Liu S, Marcucci G et al. Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int J Pharm 2010; 402: 57\u201363.","journal-title":"Int J Pharm"},{"key":"BFleu2014199_CR24","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1016\/j.biomaterials.2013.04.063","volume":"34","author":"B Yu","year":"2013","unstructured":"Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X et al. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 2013; 34: 6185\u20136193.","journal-title":"Biomaterials"},{"key":"BFleu2014199_CR25","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955\u20136960.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014199_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/leu.2014.32","volume":"28","author":"KA Beckwith","year":"2014","unstructured":"Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X et al. The CD37-targeted antibody\u2013drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 2014; 28: 1501\u20131510.","journal-title":"Leukemia"},{"key":"BFleu2014199_CR27","doi-asserted-by":"publisher","first-page":"964251","DOI":"10.1155\/2010\/964251","volume":"2010","author":"C Cassano","year":"2010","unstructured":"Cassano C, Mactier S, Mulligan SP, Belov L, Huang P, Christopherson RI . Cladribine and fludarabine nucleoside change the levels of CD antigens on B-lymphoproliferative disorders. Int J Proteomics 2010; 2010: 964251.","journal-title":"Int J Proteomics"},{"key":"BFleu2014199_CR28","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14: 1561\u20131570.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014199_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/sj.bjp.0705182","volume":"138","author":"Y Matsuoka","year":"2003","unstructured":"Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T . A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303\u20131312.","journal-title":"Br J Pharmacol"},{"key":"BFleu2014199_CR30","doi-asserted-by":"publisher","first-page":"21113","DOI":"10.1074\/jbc.272.34.21113","volume":"272","author":"AK Somani","year":"1997","unstructured":"Somani AK, Bignon JS, Mills GB, Siminovitch KA, Branch DR . Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 1997; 272: 21113\u201321119.","journal-title":"J Biol Chem"},{"key":"BFleu2014199_CR31","doi-asserted-by":"publisher","first-page":"23719","DOI":"10.1074\/jbc.M102846200","volume":"276","author":"G Craggs","year":"2001","unstructured":"Craggs G, Kellie S . A functional nuclear localization sequence in the C-terminal domain of SHP-1. J Biol Chem 2001; 276: 23719\u201323725.","journal-title":"J Biol Chem"},{"key":"BFleu2014199_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/jcb.20307","volume":"94","author":"D He","year":"2005","unstructured":"He D, Song X, Liu L, Burk DH, Zhou GW . EGF-stimulation activates the nuclear localization signal of SHP-1. J Cell Biochem 2005; 94: 944\u2013953.","journal-title":"J Cell Biochem"},{"key":"BFleu2014199_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1074\/jbc.272.2.875","volume":"272","author":"JH Brumell","year":"1997","unstructured":"Brumell JH, Chan CK, Butler J, Borregaard N, Siminovitch KA, Grinstein S et al. Regulation of Src homology 2-containing tyrosine phosphatase 1 during activation of human neutrophils. Role of protein kinase C. J Biol Chem 1997; 272: 875\u2013882.","journal-title":"J Biol Chem"},{"key":"BFleu2014199_CR34","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.1073\/pnas.0810965105","volume":"105","author":"Y Pekarsky","year":"2008","unstructured":"Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008; 105: 19643\u201319648.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014199_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4161\/mabs.19870","volume":"4","author":"S Baskar","year":"2012","unstructured":"Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C . Targeting malignant B cells with an immunotoxin against ROR1. mAbs 2012; 4: 349\u2013361.","journal-title":"mAbs"},{"key":"BFleu2014199_CR36","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1074\/jbc.272.2.952","volume":"272","author":"K Nishikawa","year":"1997","unstructured":"Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC . Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem 1997; 272: 952\u2013960.","journal-title":"J Biol Chem"},{"key":"BFleu2014199_CR37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cellsig.2005.05.016","volume":"17","author":"AW Poole","year":"2005","unstructured":"Poole AW, Jones ML . A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal 2005; 17: 1323\u20131332.","journal-title":"Cell Signal"},{"key":"BFleu2014199_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(03)00400-1","volume":"306","author":"C Wu","year":"2003","unstructured":"Wu C, Sun M, Liu L, Zhou GW . The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306: 1\u201312.","journal-title":"Gene"},{"key":"BFleu2014199_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/sj.leu.2404323","volume":"20","author":"Y Han","year":"2006","unstructured":"Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q et al. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3\/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006; 20: 1602\u20131609.","journal-title":"Leukemia"},{"key":"BFleu2014199_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/jcb.10727","volume":"90","author":"C Wu","year":"2003","unstructured":"Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW . SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 2003; 90: 1026\u20131037.","journal-title":"J Cell Biochem"},{"key":"BFleu2014199_CR41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1042\/bj20021054","volume":"368","author":"NR Paling","year":"2002","unstructured":"Paling NR, Welham MJ . Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling. Biochem J 2002; 368: 885\u2013894.","journal-title":"Biochem J"},{"key":"BFleu2014199_CR42","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012; 21: 694\u2013708.","journal-title":"Cancer Cell"},{"key":"BFleu2014199_CR43","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1073\/pnas.91.11.5007","volume":"91","author":"Z Zhao","year":"1994","unstructured":"Zhao Z, Shen SH, Fischer EH . Phorbol ester-induced expression, phosphorylation, and translocation of protein-tyrosine-phosphatase 1C in HL-60 cells. Proc Natl Acad Sci USA 1994; 91: 5007\u20135011.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014199_CR44","doi-asserted-by":"crossref","unstructured":"Borcherding N, Kusner D, Liu GH, Zhang W . ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 2014.","DOI":"10.1007\/s13238-014-0059-7"},{"key":"BFleu2014199_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","volume":"35","author":"HE Broome","year":"2011","unstructured":"Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ . ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res 2011; 35: 1390\u20131394.","journal-title":"Leuk Res"},{"key":"BFleu2014199_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3109\/10428194.2012.731599","volume":"54","author":"AH Daneshmanesh","year":"2013","unstructured":"Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grander D et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk Lymphoma 2013; 54: 843\u2013850.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014199_CR47","doi-asserted-by":"publisher","first-page":"e78339","DOI":"10.1371\/journal.pone.0078339","volume":"8","author":"M Hojjat-Farsangi","year":"2013","unstructured":"Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L et al. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One 2013; 8: e78339.","journal-title":"PLoS One"},{"key":"BFleu2014199_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1073\/pnas.1308374111","volume":"111","author":"GF Widhopf 2nd","year":"2014","unstructured":"Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci USA 2014; 111: 793\u2013798.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014199_CR49","doi-asserted-by":"publisher","first-page":"e61167","DOI":"10.1371\/journal.pone.0061167","volume":"8","author":"M Hojjat-Farsangi","year":"2013","unstructured":"Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One 2013; 8: e61167.","journal-title":"PLoS One"},{"key":"BFleu2014199_CR50","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/leu.2011.362","volume":"26","author":"AH Daneshmanesh","year":"2012","unstructured":"Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2012; 26: 1348\u20131355.","journal-title":"Leukemia"},{"key":"BFleu2014199_CR51","doi-asserted-by":"publisher","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","volume":"6","author":"J Yang","year":"2011","unstructured":"Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C . Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 2011; 6: e21018.","journal-title":"PLoS One"},{"key":"BFleu2014199_CR52","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","volume":"19","author":"M Hudecek","year":"2013","unstructured":"Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013; 19: 3153\u20133164.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014199","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:35:19Z","timestamp":1648744519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,20]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFleu2014199"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.199","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,20]]},"assertion":[{"value":"4 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A provisional patent has been filed for the use of OSU-2S to treat hematologic malignancies. The authors declare no additional competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}